Search results
Results from the WOW.Com Content Network
3,4-Methylenedioxyamphetamine (MDA) is an empathogen-entactogen, stimulant, and psychedelic drug of the amphetamine family that is encountered mainly as a recreational drug. [3] In its pharmacology , MDA is a serotonin–norepinephrine–dopamine releasing agent (SNDRA).
[118] [162] MDA is an entactogen, stimulant, and weak psychedelic similarly to MDMA. [18] Like MDMA, it acts as a potent and well-balanced SNDRA and as a weak serotonin 5-HT 2 receptor agonist. [155] [160] [161] However, MDA shows much more potent and efficacious serotonin 5-HT 2A, 5-HT 2B, and 5-HT 2C receptor agonism than MDMA.
2,3-Methylenedioxyamphetamine (2,3-MDA), an amphetamine drug This page was last edited on 5 December 2024, at 21:34 (UTC). Text is available under the Creative ...
3,4-Methylenedioxy-N-ethylamphetamine (MDEA; also called MDE and colloquially, Eve) is an empathogenic psychoactive drug. MDEA is a substituted amphetamine and a substituted methylenedioxyphenethylamine. MDEA acts as a serotonin, norepinephrine, and dopamine releasing agent and reuptake inhibitor. [1] Possession of MDEA is illegal in most ...
Amphetamine type stimulants (ATS) are a group of synthetic drugs that are chemical derivatives of the parent compound alpha-methylphenethylamine, also known as amphetamine. Common ATS includes amphetamine, methamphetamine , ephedrine , pseudoephedrine , 3,4-methylenedioxymethamphetamine (MDMA), 3,4-methylenedioxyamphetamine (MDA) and 3,4 ...
The Medicines Control Agency (MCA) and the Medical Devices Agency (MDA) merged in 2003 to form MHRA. In April 2012, the GPRD was rebranded as the Clinical Practice Research Datalink (CPRD). In April 2013, MHRA merged with the National Institute for Biological Standards and Control (NIBSC) and was rebranded, with the MHRA identity being used for ...
(R)-MDMA was first described in enantiopure form by 1978. [6] Under the developmental code names EMP-01, developed by atai Life Sciences [ 7 ] , and MM-402 , developed by MindMed [ 8 ] , it is under development for the treatment of post-traumatic stress disorder (PTSD), social phobia , and pervasive development disorders (PDDs) such as autism .
MMDA (3-methoxy-4,5-methylenedioxyamphetamine; 5-methoxy-MDA) is a psychedelic and entactogen drug of the amphetamine class. It is an analogue of lophophine , MDA , and MDMA . MMDA was described by Alexander Shulgin in his book PiHKAL .